ANZCTR search results

This study aims to improve colorectal cancer prevention by implementing a streamlined digital surveillance program, the SCOPES program, across five hospital networks in South Australia. Who is it for? You may be eligible for this study if you are an adult patient at one of the participating hospital networks in South Australia and are scheduled to undergo a lower gastrointestinal procedures (e.g. colonoscopy, flexible sigmoidoscopy, colorectal surgery) or if you have recently had a surveillance colonoscopy. Study details The SCOPES program will streamline surveillance colonoscopy practices using data linkage, natural language , and rule-based algorithms to ensure guideline-compliant care with colonoscopy frequency recommendations. The program's effectiveness will be assessed by comparing surveillance recommendations, patient experiences, and cost-effectiveness before and after implementation. Additionally, a statewide clinical data collection will be established to support ongoing research and quality improvement. It is hoped that findings from this study will help enhance consistency, reduce disparities in care, and improve patient outcomes in colorectal cancer surveillance.

This research is about finding the optimal dosage of probiotics for sick newborn babies with gestational age greater or equal to 35 weeks, admitted to Neonatal Intensive Care Unit (NICU) of Perth Children’s Hospital. Their sickness could have been either due to a medical illness or a surgical condition. We will find out if a dose higher than 3 billion probiotic bacteria per day reduces the load of harmful bacteria and increases the load of beneficial bacteria in their gut. We will measure the gut bacteria by examining their stool (poo) samples using sophisticated laboratory investigations. Specifically, we will compare the dose of 3 billion bacteria against doses of either 6 or 9 billion bacteria per day. We think that babies who receive higher dose of probiotics will have better intestinal bacteria profile and better overall health.

We will undertake a randomised online study evaluating two newly co-designed brief educational videos against a publicly available control video on the topic of osteoarthritis and diet/weight management. The aim is to understand whether communication strategy surrounding diet/weight management matters to people with osteoarthritis’ diet-related outcomes, including intentions, motivation, perceived behavioural control, implementation planning, beliefs about diet and osteoarthritis, aloneness/belongingness and validation, expectation of improvement of osteoarthritis pain, and engagement with further recommended resources. We hypothesise that the new videos (paired together or alone) will lead to greater improvements in diet-related intentions than the control video.

This is a double-blind, placebo-controlled study to assess the safety of ZE75-0267 and how this drug acts in the body in healthy volunteers. ZE75-0267 may be indicated for use in patients with Parkinson's disease, but a trial of the drug in healthy volunteers is needed before trials in Parkinson's disease patients can proceed. Who is it for? You may be eligible for this study if you are aged 18 to 65 years and are in good general health without a clinically significant medical history. Study details All healthy volunteer participants who choose to enrol in this study will be assigned by chance to receive single or multiple doses of ZE75-0267 or placebo. All participants will have their vital signs checked (heart rate, blood pressure, temperature, etc), and will provide blood and urine samples for testing. It is hoped this research will determine the maximum dose of ZE75-0267 that can be administered safely without causing severe reactions. Once the dose of ZE75-0267 has been determined in healthy volunteers, a trial investigating the efficacy of ZE75-0267 as a treatment for patients with Parkinson's disease may proceed.

The purpose of this study is to develop a dataset of micro-elastography images co-registered to ex vivo images of breast tissue. Who is it for? You may be eligible for this study if you are a woman aged 18 years or older, you have been diagnosed with invasive or in situ carcinoma and you are eligible for breast conserving surgery based on clinical evaluation by the Investigator. Study details The images will be acquired from fresh breast specimens using the ORM-P2 system - a new handheld imaging device being developed for margin assessment using micro-elastography during breast conserving surgery. Participants undergoing breast conserving surgery who consent to the study will have their fresh breast specimens collected from theatre and scanned using the ORM-P2 investigational device, prior to routine pathology testing. It is hoped this research will determine whether use of the ORM-P2 device is effective at developing a dataset of co-registered quantitative micro-elastography ex vivo images of breast tissue.

The Intergenerational Childhood Adversity and Lifetime Morbidity (I-CALM) study extends a previously approved project (MUSP-CALM) that linked a prospective birth cohort recruited at the Mater Hospital in the 1980’s to administrative health data of emergency department (ED) presentations, hospital admissions and contacts with mental health services up to 31 December 2020 (HREC/2022/QMS/83690). MUSP-CALM sought to study the effects of childhood adversity on health outcomes up to 40 years old. With I-CALM, we now seek to anonymously link the same birth cohort to the Perinatal Data Collection (PDC) to a) study their obstetric history and the perinatal history of their children and, b) link children’s perinatal records to their ED presentations and hospital admissions in the same way as we did with their mothers. The new I-CALM dataset will resultantly include two generations of data regarding heath service use, as well data on the 1st generation’s (children of the original mothers) agency reported child maltreatment data, socio-economic information (both already in the CALM dataset). This will enable the study of intergenerational health outcomes in the 2nd generation (grandchildren of the original mothers) relative to the childhood adversity experience by their mothers. The results from this study will provide evidence of intergenerational risk factors for health service use, which could tailor preventative interventions and/or inform risk tools able to identify at-risk individuals in the next generation. We hypothesise that maternal childhood adversity are associated with increased health service use and community mental health service use of their children compared to children with mothers who did not have childhood adversity. We also hypothesise that maternal childhood adversity is associated with higher instances of perinatal complications compared to mothers without previous childhood adversity.

Fifty-one percent of our current Australian population were born with ovaries and 6 million are now aged 40 or over; ie. at or approaching perimenopause and menopause, but very few clinicians have actually received training or education regarding menopause and its care. This study to aims to determine if the simple intervention proposed (combining education, reinforcement and telehealth) is a feasible approach to raise menopausal-awareness & training of your average primary care clinician (& patients too). This is especially important in rural/remote areas where telehealth follow-up may be significantly easier and patients are unlikely to have the option, and/or much longer wait times, to see menopause-specialist GPs who tend to be metropolitan-based.

This study is a multicenter, randomized, single blind (participant and Investigator blinded), placebo-controlled Phase 2 study, with a 2-group, 2-period crossover design. The aim of the study is to evaluate the safety and tolerability of NGM120 in pregnant women with HG, as well as to obtain evidence of relief of HG symptoms, as measured by PRO, including PUQE-24, HELP, nausea numerical rating scale (NRS), daily activities NRS, and well-being NRS. The study aims to show that NGM120 is safe to take and able to relieve HG symptoms (severe nausea and vomiting) in pregnant women by completing patient questionnaires.

This study aims at evaluating effect of LBBAP on clinical outcomes in comparison to RVP which has been a gold standard for six decades. The study hypothesis is that the LBBAP is more effective for pacing in patients with mild LV dysfunction or normal LV function. The study is aimed at evaluating LBBAP's efficacy in patients with LVEF >35%. Primary outcome measure is effect on LVEF. Secondary outcome measures include incidence of heart failure hospitalization, new onset atrial fibrillation and evaluation of structural changes in heart. The minimum follow up in this trial was 1 year.

The current study aimed to investigate the efficacy of two interventions, namely self-compassion (SC) and behavioural activation (BA), for academic worry in undergraduate students. We also examined the maintenance effects of the two interventions at 3- and 6-month follow-ups. Furthermore, we tested potential mechanisms of change in academic worry by focusing on experiential avoidance and intolerance of uncertainty. Undergraduate participants with moderate levels of academic worry were randomly assigned to behavioural activation, self-compassion, or control conditions, which included two in-person sessions targeting academic worry. We expected that (H1) Compared to the control condition, participants in both SC and BA conditions would show lower levels of academic worry, general worry, experiential avoidance, and intolerance of uncertainty at post-interventions, and at 3- and 6-month follow-ups. (H2) Experiential avoidance and intolerance of uncertainty at post-intervention and/or at 3-month follow-up would mediate the effects of BA and SC on academic worry at 3- and 6-month follow-ups.